IMU 1.85% 5.3¢ imugene limited

prrs vaccine proves highly effective, page-5

  1. 27 Posts.
    Report in today's Australian Life Scientist
    http://www.biotechnews.com.au/index.php?id=1494073475&eid=-2

    ============================================

    Biotech briefs
    Imugene to commercialise, Viralytics to present, Solbec eyes expansion
    Dylan Bushell-Embling 09/09/2008 15:07:00

    Animal health company Imugene [ASX: IMU] has reported small losses this financial year, but has made progress towards commercialising two products.

    The company recorded a net loss of $1.9 million, and a net cash outflow of $1.2 million, and the company said it has developed two animal vaccines with healthy earning potential.

    The first, a vaccine for porcine reproductive and respiratory syndrome (PPRS), has been tested and the company is currently seeking licensees. Imugene will soon undergo final trials of the second, a vaccine for coccidiosis in chickens, which will be tested to determine the optimal dosage.
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
5.3¢
Change
-0.001(1.85%)
Mkt cap ! $389.5M
Open High Low Value Volume
5.5¢ 5.6¢ 5.3¢ $615.0K 11.39M

Buyers (Bids)

No. Vol. Price($)
25 2977440 5.3¢
 

Sellers (Offers)

Price($) Vol. No.
5.4¢ 283236 4
View Market Depth
Last trade - 16.10pm 30/07/2024 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.